Home
3D Cell Culture Conference
19 February - 20 February 2020
3D Cell Culture Conference

 

SAE Media Group’s 4th Annual Conference
3D Cell Culture
February 19-20, 2020 | London, Copthorne Tara, United Kingdom
-------------------------------------------------------------------------

Cell Culture in an important tool for research and development within the life science industry. OThe global 3D Cell Culture Market market is valued at USD 1069.28 Million and is expected to grow with a CAGR of 25.31% over the forecast period. Researchers globally are realizing the potential of 3D cell culture for various applications, including models for personalized medicine, complex and multi-cell type models, translation and clinical and industrial applications.


Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.


SAE Media Group’s 3D Cell Culture conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.
 

FEATURED SPEAKERS

Alexander D. Graham

Alexander D. Graham

Investigator Scientist, MRC Harwell Institute
Andrea Leonard

Andrea Leonard

Senior Scientist, TreeFrog Therapeutics
Asli Akidil

Asli Akidil

Cell and Molecular Scientist, AstraZeneca
Floriane Groell

Floriane Groell

Research Associate, Biopharmaceutical Sciences department, University of Geneva
Jason Ekert

Jason Ekert

Head of Complex In Vitro Models, GlaxoSmithKline
Kenny Dalgarno

Kenny Dalgarno

Professor of Manufacturing Engineering, Newcastle University
Leonard Both

Leonard Both

Senior Quality Assessor, Biologicals/Biotechnology Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
Michele Zagnoni

Michele Zagnoni

Reader, University Of Strathclyde
Philip Hewitt

Philip Hewitt

UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Rhiannon David

Rhiannon David

Associate Principal Scientist, AstraZeneca
Samuel Jackson

Samuel Jackson

Programme Manager, Disease Models, NC3Rs
Simone Stahl

Simone Stahl

Associate Principal Scientist, AstraZeneca
Stefan Przyborski

Stefan Przyborski

Professor of Cell Technology, Durham University
Veronique Barban

Veronique Barban

Expert Virology, Sanofi Pasteur
Wendy Rowan

Wendy Rowan

Scientific Director, GSK

Alessandro Fiorenzano

Postdoctoral fellow , Lund University
Alessandro Fiorenzano

Dr. Fiorenzano holds a post-doctoral position in Prof. Parmar’s group at the Department of Developmental and Regenerative Neurobiology, Lund University, Sweden. He has a Bachelor's and Master's degrees in Biology from the University of Naples Federico II. He obtained his PhD in Molecular and Cellular Biotechnology at the Italian National Research Council Institute of Genetics and Biophysics, where he studied the impact of the extracellular microenvironment on pluripotency and differentiation of embryonic stem cells (ESCs). His current focus is on investigating the molecular mechanisms underlying neuronal specification that drive controlled differentiation of human stem cells into subtype-specific dopamine neurons for use in stem cell-based therapies for Parkinson’s disease.

Alexander D. Graham

Investigator Scientist, MRC Harwell Institute
Alexander D. Graham

Dr Alexander Graham, an Investigator Scientist at MRC Harwell Institute, is a biofabrication specialist with 8 years of experience in bioprinting and 3D tissue models. During his doctoral studies at the University of Oxford (Hagan Bayley group), he co-invented a high-resolution drop-on-demand 3D bioprinter of cellular components and living mammalian cells. This work set the scientific foundation for synthetic tissue company OxSyBio (UK, 2014-2019), where Alex led biofabrication developments. This included a successful collaboration with MRC Harwell Institute on the development of a high throughput 3D model of white adipose tissue for use in mechanistic studies of metabolic diseases.

Andrea Leonard

Senior Scientist, TreeFrog Therapeutics
Andrea Leonard

Andrea Leonard originally trained in engineering physics (PhD in Applied Mechanics from Caltech in 2013) before transitioning into bioengineering and stem cell research as a postdoc at the University of Washington –Seattle (2014-2018). During her postdoc, she utilized both micro-fabrication techniques and tissue engineering approaches to measure and enhance the contractile function of human stem cell derived cardiomyocytes. Andrea joined TreeFrog Therapeutics as Senior Scientist in February 2019 to lead 3D iPSC differentiation projects.

Asli Akidil

Cell and Molecular Scientist, AstraZeneca
Asli Akidil

Asli Akidil is a senior scientist within the Oncology combinations safety team in the clinical pharmacology and safety sciences department based in Cambridge, UK. The team is responsible for designing bespoke preclinical studies to assess risk and the mechanisms underlying toxicity of oncology combinations. Asli has a specific expertise in implementing a humanised bone marrow-on-a-chip model to AZ’s drug discovery and development pipeline to inform optimal clinical trial designs. Asli has experience in developing imaging end points to in vitro technologies and applying them to understand mechanistic toxicity of cancer therapies.

Floriane Groell

Research Associate, Biopharmaceutical Sciences department, University of Geneva
Floriane Groell

Floriane Groell is currently a Senior Scientist within the Cell and Gene Therapies Development department at Novartis, in Basel (Switzerland).
She holds a PhD in Biopharmaceutical Sciences from the University of Geneva. During her thesis at the Geneva-Lausanne School of Pharmaceutical Sciences (EPGL), she worked on the biophysical characterization of therapeutic proteins aggregates applying 3D subcutaneous cell culture models for immunogenicity assessment. Before her doctoral studies, Floriane graduated her Master in Biotechnology from the University of Technology of Compiègne (France). She holds a Bachelor degree in Biochemistry from the University Claude Bernard Lyon 1 (France).
Floriane grew up near Chamonix Mont-Blanc. She likes hiking and skiing, and finds peace of mind in yoga practice now for over 10 years.
 

Hilary Pollard

Product Manager - Cell Based Assays, Promega UK Ltd
Hilary Pollard

Promega is a global leader in providing innovative solutions and technical support to life scientists asking fundamental questions about biological processes and applying scientific knowledge to discover new therapeutics, diagnose and treat diseases and use genetics for human identification. Promega has a range of cell-based assays for phenotypic analysis of 3D cell cultures.

Jason Ekert

Head of Complex In Vitro Models, GlaxoSmithKline
Jason Ekert

I head the Complex In Vitro Models group in the R&D Platform Technology & Sciences organization at GlaxoSmithKline. I lead an integrated enterprise strategy for sustained, portfolio driven growth in R&D applications of human-relevant and translatable complex in vitro models (eg Spheroids, Organoids, MPS and bioprinting). Before coming to GSK I spent 11 years at Janssen BioTherapeutics in early biotherapeutic drug discovery in target discovery, drug validation and MOA studies applying complex cell-based assays across multiple therapeutic areas. My current focus at GSK is to improve predictive validity of early preclinical models leading to better characterized molecules, decreased R&D cycle time and a reduction in attrition.

Kenny Dalgarno

Professor of Manufacturing Engineering, Newcastle University
Kenny Dalgarno

Kenny Dalgarno is Sir James Woodeson Professor of Manufacturing Engineering at Newcastle University, and is Deputy Director of the Arthritis Research UK Tissue Engineering Centre, Deputy Director of the UK EPSRC Centre for Innovative Manufacture in Medical Devices, the Newcastle University lead investigator for the UK EPSRC Centre for Doctoral Training in Additive Manufacture and 3D Printing. He researches in the area of additive manufacture and biofabrication, with an increasing emphasis on applications in biomedical engineering, tissue engineering, and regenerative medicine, with work supported by the EPSRC, the European Commission, Arthritis Research UK, the NC3Rs, and industry.

Leonard Both

Senior Quality Assessor, Biologicals/Biotechnology Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
Leonard Both

Dr Leonard Both is a Senior quality assessor at the Medicines and Healthcare products Regulatory Agency (MHRA) in London, UK. He works in the Biologicals & Biotechnology Unit of the MHRA Licensing Division. Before joining MHRA, he performed quality assessments of diagnostics at Public Health England (PHE, previously called the Health Protection Agency) and worked at the European Medicines Agency (EMA). He is a board member of the Control Programme Board (CPB) at the National Institute of Biological Standards and Controls (NIBSC). Leonard holds a PhD degree in molecular immunology from the University of London.

Michele Zagnoni

Reader, University Of Strathclyde
Michele Zagnoni

Dr Michele Zagnoni leads a multidisciplinary research group focussed on the development of microfluidic technologies for healthcare applications, including fundamental biological research, drug screening, personalized medicine therapy, organ-on-a-chip and synthetic biology (www.zagnonilab.com). He is the co-founder and Chief Scientific Officer of ScreenIn3D.

Philip Hewitt

UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Philip Hewitt

?I originally trained as a Medical Biochemist at the University of Birmingham (1986-1989). I worked as a Research Assistant in the Pharmacology and Toxicology Department at Imperial College, London where I received my PhD in the lab of Dr Sharon Hotchkiss. The main theme of the research project was “percutaneous absorption: metabolic and kinetic parameters”. In 1996, I transferred to The University of California, San Francisco, in the Dermatology Department; I spent 18 months there under the guidance of Prof. Howard Maibach. In 1998 I started a permanent position in the Institute of Toxicology at Merck KGaA in Germany, where I established the Molecular Toxicology Group. I am currently responsible for early cytotoxicity screening, hepatotoxicity methods, biomarker monitoring, CYP induction studies, genotoxicity testing and cytokine screening. I work with several PhD students, on external collaborative projects and I am team representative on several internal pharmaceutical projects.

Rhiannon David

Associate Principal Scientist, AstraZeneca
Rhiannon David

Rhiannon is an Associate Principal Scientist in Clinical Pharmacology and Safety Sciences at AstraZeneca, Cambridge, UK. Rhiannon received her PhD from the University of Birmingham in 2009 following which she joined the Department of Medicine at Imperial College, London, where she spent 5 years as a postdoctoral scientist, undertaking research into the genotoxicity of mixtures. During this time, Rhiannon developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. Rhiannon joined AstraZeneca in 2015 where she has led the development of a bone marrow microphysiological system for improved pre-clinical safety assessment.

Samuel Jackson

Programme Manager, Disease Models, NC3Rs
Samuel Jackson

Dr Jackson was awarded a PhD in Neurobiology in 2004 for work studying the role of the cannabinoid system in neurodegeneration related to multiple sclerosis. During postdoctoral positions at the University of Wisconsin – Madison, UCL and QMUL, he developed and employed animal and in vitro models of demyelinating disease to probe therapeutic approaches to remyelination and neuroprotection. Following 3 years at Eli Lilly working on the neurobiology and treatment of Alzheimer’s disease, Dr Jackson left the lab to apply his knowledge of animal and alternative modelling at the NC3Rs. He is currently managing a programme of work to enable the development and uptake of human tissue based models, microphysiological systems and other alternative methods to diverse research areas, including cancer and safety pharmacology.

Simone Stahl

Associate Principal Scientist, AstraZeneca
Simone Stahl

Simone Stahl completed her PhD in tumour immunology at the German Cancer Research Centre in Heidelberg. She joined AstraZeneca’s safety function initially in Alderley Park then Cambridge, UK. In Molecular Toxicology Simone contributed to AstraZeneca’s preclinical hepatotoxicity strategy developing in vitro models for hepatic and other organ toxicities. She has since continued to gain expertise in drug transporters and their role in organ injury, drug disposition and drug drug interactions. In ADME Sciences Simone champions the evaluation of novel in vitro systems for DMPK applications. Throughout her career Simone supported investigative programs for drug projects from the toxicity as well as ADME perspective.

Stefan Przyborski

Professor of Cell Technology, Durham University
Stefan Przyborski

Professor Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, tissue engineering and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 110 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of Reprocell Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. Professor Przyborski is developing new and innovative ways to manage the growth and function of cultured cells. These enabling technologies have multiple applications and will be particularly relevant to bioengineering models of human tissues to advance basic research and drug discovery.

Therese Kallur

Director Business Development, BioLamina AB
Therese  Kallur

Therése Kallur is heading Business Development at BioLamina with extensive experience in managing scientific collaborations, joint ventures, R&D, product pipeline and development. She graduated from Lund University with a BSc in Psychology , MSc in Molecular biology, and later on a PhD in Neurobiology. She completed post doctoral studies at Max-Planck-Institute for Metabolism Research in 2010 after which she joined BioLamina.

BioLamina offers reagents for biomedical research and is built around knowledge on production and cell applications for human recombinant laminins. BioLamina’s vision is to become a leading provider of tools for primary cell culture to enable life-saving therapies.
 

Veronique Barban

Expert Virology, Sanofi Pasteur
Veronique Barban

Virology Expert in the global Research & Non-Clinical Safety Department of Sanofi Pasteur
Training /expertise: Molecular and Cellular Virologist with 30 years of experience in Vaccine Research in Pharmaceutical Industry. Contribution to conception, evaluation and development of live-attenuated viral vaccines for human use. Large expertise in vaccines against flavivirus infection, including 15 years on the development of DengVaxia, the first licenced vaccine against dengue (authoring and co-authoring of several publications and patents on vaccine development and characterization). Main other expertise areas include Yellow Fever, Japanese Encephalitis and Zika viruses, Hepatitis A and C infection, SRAS, CMV and HIV (canaripox vectors)
Current centres of interest: Since few years, growing interest in animal substitution (3Rs) and in vitro cellular models able to mimic some aspects of viral pathogenesis
 

Wendy Rowan

Scientific Director, GSK
Wendy Rowan

I started my career at Guy’s Hospital Medical School, before transitioning to industry. I have worked for GSK and its legacy companies for over thirty years. Immunology has been a common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases. In April 2019, I joined the Novel Human Genetics Research Unit with a focus on using genetics to guide target selection for drug discovery. With the aim of reducing attrition in drug discovery, I have a long standing interest in developing and accessing better human translational models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Jason Ekert

Jason Ekert, Head of Complex In Vitro Models, GlaxoSmithKline

clock

9:10

First Applications of 3D Bioprinted Tissue Models for Drug Screening

Petra Kerscher

Petra Kerscher, Senior Scientist, Merck KGaA

  • Use of 3D bioprinting in Pharma industry
  • Validation of printed tissue models
  • The importance of biomaterials for 3D bioprinting
  • Outlook of 3D bioprinting for drug screening applications
     
  • clock

    9:50

    3D Printing of Medicines: A Digital Pharmacy Era

    Patricija Januskaite

    Patricija Januskaite, Senior Formulation Scientist, FabRx Ltd

  • An introduction on the need for personalised medicines
  • Discussion on the clinical and wider healthcare impact of 3D printing
  • Explanation of the various 3D printing technologies, and their benefits / drawbacks for medicine production
  • Discussion on the current challenges to the clinical integration of 3D printing
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    3D Bioprinted Human Skeletal Muscle Models for In Vitro Physiological Drug Screening

    Hansjoerg Keller

    Hansjoerg Keller, Senior Investigator I, Novartis

  • In vitro human microphysiological assays boost drug development
  • 3D bioprinting enables the fabrication of complex human tissue in vitro models for drug discovery
  • 3D bioprinted human skeletal muscle models mimic pharmacological regulation of muscle contractile force
  • 3D bioprinted contractile human skeletal muscle models allow functional screening of test compounds
  • clock

    11:40

    PANEL DISCUSSION: The use of bioprinting for screening

  • Opportunities for bioprinted organoids for screening purposes
  • Challenges in compatibility of HTS for 3D models
  • How we can improve 3D modelling for efficacy and safety testing and further applications
     
  • Jason Ekert

    Jason Ekert, Head of Complex In Vitro Models, GlaxoSmithKline

    Petra Kerscher

    Petra Kerscher, Senior Scientist, Merck KGaA

    Hansjoerg Keller

    Hansjoerg Keller, Senior Investigator I, Novartis

    Patricija Januskaite

    Patricija Januskaite, Senior Formulation Scientist, FabRx Ltd

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Reactive Jet Impingement: A New 3D Printing Process for High Cell Density Gels

    Kenny Dalgarno

    Kenny Dalgarno, Professor of Manufacturing Engineering, Newcastle University

  • Introduction to the reactive jet impingement process
  • Outline value of high cell density gels
  • Case studies on printing musculoskeletal micro-tissues
     
  • clock

    14:00

    3D Extracellular matrix scaffolds and hydrogels for target discovery and drug profiling

    Lisa Longato

    Lisa Longato, Head of Fibrosis, Engitix Ltd

  • The ECM exhibits an important functional role in the control of key cellular events
  • The contribution of ECM is often overlooked in target and drug discovery efforts
  • Engitix has developed unique technologies allowing the development of human tissue-specific and disease-specific ECM biomaterials for target discovery and drug profiling purposes
     
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    3D Bioprinting Engineering Artificial Respiratory Tract Tissue

    Naheem Yaqub

    Naheem Yaqub, PhD Candidate, University College London in Collaboration with GSK

  • Ethos and background of why the need to develop and improve upon the current gold-standard in vitro models of the respiratory epithelium exists
  • The primary research aim of this project is to create the first bioprinted, multi-cellular, 3D model of the upper respiratory mucosa; with various collaborations involved in the project
  • Data outlining key stages towards a new ALI culture methodology involving in vitro primary human bronchial epithelial cell culture on collagen layers
  • Hydrogels used for extended culture and differentiation of primary HBECs at an air-liquid interface
  • Preliminary bioprinting of primary human lung fibroblasts
     
  • clock

    16:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:00

    Registration & Coffee

    clock

    9:00

    Chairs' Opening Remarks

    Stefan Przyborski, Professor of Cell Technology, Durham University

    Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

    clock

    9:10

    The Development and Application of 3D Culture Techniques to Construct Models of Human Tissues

    Stefan Przyborski, Professor of Cell Technology, Durham University

    • Overview of 3D cell culture technologies;
    • Impact and importance of 3D cell culture;
    • Beyond 3D cell culture as a technique, applications to building human tissues in vitro;
    • New innovations and developments to further enhance 3D technology

    clock

    9:50

    Organ-on-a-chip: Can we finally replace animals in pharmaceutical research

    Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

    • Development of human, translatable in vitro MPS models
    • Status of OOAC field; current models and industry “validation”
    • Context of use: focus on safety testing
    • Future: can we replace animals or even clinical trials?
     

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Complex In Vitro Models for preclinical oncology drug development

    Jason Ekert, Head of Complex In Vitro Models, GlaxoSmithKline

  • Characterization and validation criteria for Oncology models
  • Case studies- 
  • Avascular and vascular microfluidic tumor models
  • Tumor Organoids for combination drug screening
  • Future direction
     
  • clock

    11:40

    3D-models for infectious diseases and vaccines

    Veronique Barban, Expert Virology, Sanofi Pasteur

    • Potential and Limits of 3D-models for industrial development of human vaccines
    • Case study: 2D and 3D liver models for yellow fever virus viscerotropism assessment
     

    clock

    12:20

    Tools for evaluating cellular health and energy metabolism in 3D cell culture models

    Hilary Pollard, Product Manager - Cell Based Assays, Promega UK Ltd

  • Considerations for choosing the correct assay for 3D cultures
  • Cellular energy metabolism assays for 3D Cultures
  • Multiplexing assays to maximise data output per sample
     
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Development of microphysiological systems to improve pre-clinical safety

    Rhiannon David, Associate Principal Scientist, AstraZeneca

  • Human-sourced MPS provide an opportunity to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models.
  • Outline context of use of MPS at AstraZeneca and examples of data generated from these systems that demonstrate the utility of MPS for safety assessment
  • Development of a bone marrow microphysiological system – set up, experimental design and positioning in the drug discovery pipeline
  • clock

    14:40

    PANEL DISCUSSION: Adopting new technologies for 3D models

    • An outlook of new and developing technologies for 3D cell culture models
    • Challenges and barriers in the adoption of new technology
    • What is required to make a decision on adoption and what is needed to promote adoption in industry?
     

    Stefan Przyborski, Professor of Cell Technology, Durham University

    Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

    Floriane Groell, Research Associate, Biopharmaceutical Sciences department, University of Geneva

    Samuel Jackson, Programme Manager, Disease Models, NC3Rs

    Wendy Rowan, Scientific Director, GSK

    clock

    15:20

    Printing 3D Cell Cultures in Osteoarthritis Research

    Kenny Dalgarno, Professor of Manufacturing Engineering, Newcastle University

  • Outline the use of bioprinting in two major projects which focus on osteoarthritis:
  • Tissue Engineering & Regenerative Therapies Centre Versus Arthritis
  • CRACK-IT Challenge Project: Printing Osteoarthritis on a Chip
  • Outline the printing approaches taken, and approaches to (i) integration with downstream processes, and (ii) scale-up
  • clock

    16:00

    Afternoon Tea

    clock

    16:30

    C-Stem® technology : 3D microfluidics enabled scale up of culture and differentiation of pluripotent stem cells organoids

    Andrea Leonard, Senior Scientist, TreeFrog Therapeutics

    • In vivo like environment allows recapitulation of correct PSC topology
    • Strongly diminished cell death contributes to increased yields
    • Protection from bioreactor mechanical stress allows scale up of PSC culture in standard liquid bioreactors
    • Differentiation of PSC can be achieved within C-Stem™ by leveraging 2D protocols
     

    clock

    17:10

    Microfluidic technologies for precision medicine in oncology

    Michele Zagnoni, Reader, University Of Strathclyde

    • Maximising screening of patient tissue
    • Physiological tumour models
    • Microfluidic technologies
    • Precision medicine
     

    clock

    17:50

    Chairs' Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairs' Opening Remarks

    Stefan Przyborski, Professor of Cell Technology, Durham University

    Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

    clock

    9:10

    Regulatory outlook on 3D Cell Culture Models

    Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, Medicines & Healthcare products Regulatory Agency (MHRA)

    • An overview of the applicable regulatory guidelines
    • Validating new technology, relevant quality considerations and regulatory processes
    • Challenges for the traditional regulatory framework
     

    clock

    9:50

    Addressing unmet needs in 3D cell systems to drive replacement of animal modelling

    Samuel Jackson, Programme Manager, Disease Models, NC3Rs

  • Much progress has been made in 3D cell model development, to the point that many sub-organ level systems can now be effectively recapitulated in vitro.
  • However, there are several key areas which have yet to be effectively tackled, such as the immune system and tissue vascularization and innervation. 
  • Given that these systems or structures are implicated in most physiological processes and many disease states, making progress on these difficult to tackle topics is key to the future success of 3D modelling approaches.
  • By addressing these areas of unmet need, animal modelling paradigms will increasingly be replaced or augmented with human cell-based systems.

     

  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Reducing attrition in drug discovery through the use of human translational cellular models

    Wendy Rowan, Scientific Director, GSK

    • The challenge in drug discovery to reduce clinical attrition
    • The new generation of human translational models for use in drug discovery
    • The application and challenges in application of human translational models for drug discovery
    • Looking to the future
     

    clock

    11:40

    Biosilk 521 – a new 3D biomaterial that combines the biological instructive cues from ECM laminins with the mechanical and topological support from silk

    3D culture
    Extracellular matrix signalling
    Human brain organoids

    Therese Kallur, Director Business Development, BioLamina AB

    Alessandro Fiorenzano, Postdoctoral fellow , Lund University

    clock

    12:20

    Application of 3D models to ADME research

    Simone Stahl, Associate Principal Scientist, AstraZeneca

  • Importance of physiological features in 3D models for ADME research with a focus on drug transporters
  • Examples of current landscape of ADME 3D models and their applications
  • Transporter characterisation of renal 3D models such as organoids or microfluidic systems
  • Outlook of how ADME 3D models can be applied to drug projects
     
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Advancing in vitro haematotoxicity risk assessment with a humanised bone marrow microphysiological system (BM MPS)

    Asli Akidil, Cell and Molecular Scientist, AstraZeneca

  • Haematological toxicity is a common side effect in patients receiving cancer treatments.
  • Identifying tolerable doses/schedules in the clinic is challenging and can result in dose modifications, dose delays, or discontinuation of cancer therapy, potentially limiting therapeutic benefit.
  • A humanised bone marrow microphysiological system (BM MPS) has the potential to inform on the optimal dose and schedule for cancer treatments with haematological toxicity.
  • Recapitulating haematological toxicity of Carboplatin and Olaparib combination in a BM MPS system highlights the potential use of the system for risk assessment.
  • Case study to be described: In vitro BM MPS of Carboplatin and Olaparib combination mimicking previously conducted clinical trial study design
     
  • clock

    14:40

    3D cell culture model to mimic the human subcutaneous tissue

    Floriane Groell, Research Associate, Biopharmaceutical Sciences department, University of Geneva

  • Development of a 3D cell culture model of the human subcutaneous tissue, allowing the immunogenicity prediction of subcutaneously injected therapeutic proteins.
  • Use of hydrogels as a scaffold to mimic the visco-elastic properties of the human subcutaneous tissue in vitro. Measurement of hydrogels elastic Young's moduli and comparison with ex vivo human samples.
  • Investigation of the hydrogels cytocompatibility with a human myelomonocytic cell line (MUTZ-3) and their influence on cellular phenotype changes
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Development of a high throughput and drug responsive 3D model of white adipose tissue

    Alexander D. Graham, Investigator Scientist, MRC Harwell Institute

  • Conception and optimization of a novel biofabrication workflow for the development of 3D tissue models i.e. the bioprinting and dispensing of matrix-based cellular constructs under oil prior to media transfer 
  • A joint collaboration between OxSyBio and MRC Harwell led to the development of a 3D white adipose tissue (WAT) model for mechanistic studies of metabolic diseases
  • Extensive characterization of the adipogenic spheroid (i.e. the 3D WAT) revealed the model was reproducible, highly differentiated, had active lipid metabolism and was drug-responsive
  • Establishment of high throughput monitoring of drug-effects on 3D WAT models on a 96-well scale. Specifically, using high content-imaging of lipid phenotype and time-course metabolite measurements
  • clock

    16:30

    Chairs' Closing Remarks and Close of Day Two


    Postdoctoral fellow
    Lund University
    Investigator Scientist
    MRC Harwell Institute
    Senior Scientist
    TreeFrog Therapeutics
    Cell and Molecular Scientist
    AstraZeneca
    Research Associate, Biopharmaceutical Sciences department
    University of Geneva
    Product Manager - Cell Based Assays
    Promega UK Ltd
    Head of Complex In Vitro Models
    GlaxoSmithKline
    Professor of Manufacturing Engineering
    Newcastle University
    Senior Quality Assessor, Biologicals/Biotechnology Unit
    Medicines & Healthcare products Regulatory Agency (MHRA)
    Reader
    University Of Strathclyde
    UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology
    Merck Healthcare KGaA
    Associate Principal Scientist
    AstraZeneca
    Programme Manager, Disease Models
    NC3Rs
    Associate Principal Scientist
    AstraZeneca
    Professor of Cell Technology
    Durham University
    Director Business Development
    BioLamina AB
    Expert Virology
    Sanofi Pasteur
    Scientific Director
    GSK

    Sponsors

    Exhibitors

    Official Media Partner

    Supporters

    Focus Days

    3D Bioprinting Focus Day

    3D Bioprinting Focus Day

    Copthorne Tara Hotel
    18 February 2020
    London, United Kingdom

    Preliminary Attendees

    Download

    Speaker Interview with Alexander D Graham

    Download

    Speaker Interview with Michele Zagnoni

    Download

    Speaker Interview with Kenny Dalgarno

    Download

    Chair Invite Letter

    Download

    Speaker Interview with Stefan Pryzborski

    Download

    Full Programme

    Download

    2020 Conference Speakers

    Download

    Focus Day 3D Bioprinting

    Download

    3D Cell Culture Brochure 2020

    Download

    Past Attendees 2017-2019

    Download

    2019 - 'Novel approaches to study cell health and signalling in 3D microtissues' by Marta Rucka - Promega

    Download

    2019- 'Metabolic equilibrium in 3D environments: a key to stable, reproducible, mimetic tissues' by Krzysztof Wrzesinski- CelViv

    Download

    2019 - 'From the Well to the Cell: Novel Technologies for Imaging and Analysis in 3D Cell Culture Workflows' by Wouter Strijker-

    Download

    2019 - 'Tools, not Toys: From Innovation to Regulatory Application' by William B. Mattes - FDA US

    Download

    2019- 'Crack-it:Development of 3D eye models for early assessment of retinal toxicity' by Phil Hewitt - Merck

    Download

    Sponsors


    BioLamina

    Sponsors
    http://www.biolamina.com

    Our BiolamininTM substrates are animal component-free, defined, full-length laminin cell culture matrices that can be used for a variety of applications, like the expansion of human pluripotent stem cells and differentiation and maintenance of different specialized cell types, such as hepatocytes, cardiomyocytes, and neural cells. The biologically relevant cell-matrix interaction gives more consistent cellular responses, more standardized experiments, improve the differentiation potential and keep adult cells mature for a significantly longer time in culture than has previously been feasible. With our cell therapy grade products, BioLamina can support scientists throughout their cell therapy development process – from concept to commercialized therapy. Our Biosilk 521 is a new 3D platform that combines the biological instructive cues from ECM laminins with the mechanical and topological support from silk, allowing engineered, controllable and tunable organoids.


    Promega

    Sponsors
    https://www.promega.co.uk

    Promega is a global leader in providing innovative solutions and technical support to life scientists asking fundamental questions about biological processes and applying scientific knowledge to discover new therapeutics, diagnose and treat diseases and use genetics for human identification. Promega offers a portfolio of cell-based assays for phenotypic analysis of 3D cell cultures.

    Exhibitors


    CELLINK

    Exhibitors
    https://cellink.com/global/

    CELLINK is a global leader in developing and delivering life-science solutions, equipping hundreds of labs and thousands of scientists worldwide with cutting-edge technologies that fuel groundbreaking scientific breakthroughs. With a commitment to quality and innovation, our bioprinters, imaging systems and bioinks have contributed to revolutionary advancements in academic and clinical medicine.

    CELLINK’s solutions advance and accelerate the discovery process for customers in more than 50 countries, including university, hospital, pharmaceutical, public and commercial laboratories. Our domain knowledge, dedication to innovation and passion for excellence has positioned us as the driving market force in the fields of bioprinting and 3D cell culturing. We strive to push the limits of what is possible in regenerative medicine and pharmaceutical development, inspiring and empowering collaborators to expand their horizons and overcome any challenge they face. Join us on our journey to change the future of medicine: www.cellink.com.



    Manchester BIOGEL

    Exhibitors
    https://manchesterbiogel.com

    Manchester BIOGEL is a leader in the design and manufacture of 3D synthetic peptide hydrogels that are redefining cell culture and 3D bioprinting for life science. Our biologically relevant PeptiGels® and PeptiInks® mimic the cell micro-environment and have tuneable properties to simulate the natural environment of all human tissues. Our PeptiGels® are specifically designed and tailored to overcome the key limitations with current biomaterials for regenerative medical applications. Our PeptiInks® are specifically designed to encapsulate and print cells with precise structural definition. Everything is 100% ethical, animal free and chemically defined, and are supplied with no batch-to-batch variability. This gives you the confidence to achieve reliable and consistent results every time, and with the adage of being clinically translatable, you have the potential to deliver life-changing therapies.


    Merck

    Exhibitors
    http://SigmaAldrich.com

    OUR LIFE SCIENCE BUSINESS ACCELERATES ACCESS TO BETTER HEALTH FOR EVERYONE

    Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific re-search and production, to liquid crystals for smartphones and LCD televisions.

    From drug discovery and development to manufacturing and diagnostics, we are dedicated to solving the toughest problems in life science by collaborating with the global scientific community. Our 300,000 products range from lab water systems to gene editing tools, antibodies, cell lines and end-to-end systems to manufacture drugs. We work closely with our customers from academia, biotech and pharma to help deliver the promise of their work better, faster and safer.

    To learn more visit SigmaAldrich.com


    Media Partners


    Genetic Engineering News

    Official Media Partner
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    3DMedNet

    Official Media Partner
    https://www.3dmednet.com/

    3DMedNet is an online community providing the latest news, opinions and peer-reviewed journal articles focused on the applications of 3D printing technologies in medicine, including 3D-printed medical devices, surgery, pharmaceuticals, bioprinting, dentistry and the regulatory landscape. Visit 3DMedNet today at: www.3dmednet.com


    Labiotech.eu

    Official Media Partner
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

    Media Partners


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    MedTube

    Supporters
    https://medtube.net/



    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.